The 27th \u201cStock Exchange Company of the Year\u201d gala, a competition organized by the editorial team of Puls Biznesu, is now behind us. Each year, the selection of the best of the best is made by 100 stock market analysts, investment advisors, and asset managers representing brokerage houses and offices, pension funds, and investment funds. In the latest edition of the poll, we received the highest scores in the \u201cGrowth Prospects\u201d category. We placed third in the categories \u201cHighest Innovation in Products and Services\u201d and \u201cInvestor Relations.\u201d In the overall ranking, we are once again in the TOP3.<\/p>\n
In its latest article, Puls Biznesu reminds readers that we are on the final straight before registering our first drug on the EU market.<\/p>\n
\u201cBioceltix is on the podium for the second consecutive time, standing out among publicly listed biotech companies because it develops drugs not for humans, but for animals. And this makes it significantly faster,\u201d we read in the article by editor Marcel Zato\u0144ski.<\/p>\n
\u201cBioceltix stands out among biotechnology companies listed on the WSE in terms of the advancement of its work, as applications have already been submitted for the registration of two drug candidates\u2014one for osteoarthritis in dogs and another for arthritis in horses. In the case of registration for dogs, an extension of indications to include atopic dermatitis is also planned. Of course, in veterinary biotechnology, reaching this stage is less complex than in the case of drugs intended for humans, but clinical trial data provide a strong proof of concept for the company\u2019s portfolio projects,\u201d comments Beata Szparaga-Wa\u015bniewska, analyst at mBank Brokerage Office.<\/p>\n